Forced degradation of therapeutic proteins
- PMID: 22083792
- DOI: 10.1002/jps.22812
Forced degradation of therapeutic proteins
Abstract
The scope of this paper is to review approaches used for forced degradation (synonym, stress testing) of therapeutic proteins. Forced degradation studies play a central role in the development of therapeutic proteins, for example, for candidate selection, molecule characterization, formulation development, assay development, and comparability studies. Typical stress methods are addressed within this review, such as exposure to elevated temperatures, freeze-thawing, mechanical stress, oxidation, light, as well as various materials and devices used in the clinics during final administration. Stability testing is briefly described as far as relevant to the discussion of forced degradation studies. Whereas stability-testing requirements are defined in regulatory guidelines, standard procedures for forced degradation of therapeutic proteins are largely unavailable, except for photostability. Possible selection criteria to identify appropriate stress conditions and recommendations for setting up forced degradation studies for the different phases of development of therapeutic proteins are presented.
Copyright © 2011 Wiley Periodicals, Inc.
Similar articles
-
Forced degradation studies of biopharmaceuticals: Selection of stress conditions.Eur J Pharm Biopharm. 2016 Jan;98:26-46. doi: 10.1016/j.ejpb.2015.10.016. Epub 2015 Nov 2. Eur J Pharm Biopharm. 2016. PMID: 26542454 Review.
-
Practical Approaches to Forced Degradation Studies of Vaccines.Methods Mol Biol. 2016;1403:853-66. doi: 10.1007/978-1-4939-3387-7_49. Methods Mol Biol. 2016. PMID: 27076171
-
Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins III: collapse during storage at elevated temperatures.Eur J Pharm Biopharm. 2013 Oct;85(2):240-52. doi: 10.1016/j.ejpb.2013.05.009. Epub 2013 May 31. Eur J Pharm Biopharm. 2013. PMID: 23727369
-
Study of forced degradation behavior of eletriptan hydrobromide by LC and LC-MS and development of stability-indicating method.J Pharm Biomed Anal. 2009 Nov 1;50(4):622-9. doi: 10.1016/j.jpba.2009.01.034. Epub 2009 Feb 6. J Pharm Biomed Anal. 2009. PMID: 19250786
-
Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review.Int J Pharm. 2018 May 30;543(1-2):328-344. doi: 10.1016/j.ijpharm.2018.04.007. Epub 2018 Apr 7. Int J Pharm. 2018. PMID: 29635054 Review.
Cited by
-
End-to-End Approach to Surfactant Selection, Risk Mitigation, and Control Strategies for Protein-Based Therapeutics.AAPS J. 2022 Dec 5;25(1):6. doi: 10.1208/s12248-022-00773-3. AAPS J. 2022. PMID: 36471030
-
Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics.Antib Ther. 2022 Nov 11;6(1):13-29. doi: 10.1093/abt/tbac029. eCollection 2023 Jan. Antib Ther. 2022. PMID: 36683767 Free PMC article. Review.
-
Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.J Pharm Sci. 2014 Mar;103(3):796-809. doi: 10.1002/jps.23839. Epub 2014 Jan 22. J Pharm Sci. 2014. PMID: 24452866 Free PMC article.
-
Characterizing and Minimizing Aggregation and Particle Formation of Three Recombinant Fusion-Protein Bulk Antigens for Use in a Candidate Trivalent Rotavirus Vaccine.J Pharm Sci. 2020 Jan;109(1):394-406. doi: 10.1016/j.xphs.2019.08.001. Epub 2019 Aug 7. J Pharm Sci. 2020. PMID: 31400346 Free PMC article.
-
A Cell-Based Strategy for Bioactivity Determination of Long-Acting Fc-Fusion Recombinant Human Growth Hormone.Molecules. 2019 Apr 9;24(7):1389. doi: 10.3390/molecules24071389. Molecules. 2019. PMID: 30970583 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources